Journal
JOURNAL OF AAPOS
Volume 19, Issue 2, Pages 116-118Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaapos.2014.11.006
Keywords
-
Categories
Funding
- Research to Prevent Blindness Inc, New York
Ask authors/readers for more resources
PURPOSE To report the, intraocular pressure (TOP) lowering ability and side-effect profile of echothiophate iodide (El) in the control of glaucoma in aphakic and pseudophakic eyes of children. METHODS The medical records of all aphakic and pseudophakic children treated with El for TOP lowering after developing glaucoma were retrospectively reviewed. RESULTS A total of 32 eyes of 21 children were included. Mean age at cataract removal was 3.9 months (range, 5 days-2.7 years). Mean age of glaucoma diagnosis was 3.2 years (range, 40 days-12 years). Mean duration from cataract removal and diagnosis of glaucoma was 2.9 years (range, 16 days-12 years). EI reduced TOP in 31 of 32 eyes. Mean baseline TOP (29.1 +/- 5.3 mm Hg) dropped to 19.6 +/- 6.7 mm Hg. Six eyes had 1013 spikes that could not be controlled with other medications when commercial unavailability led to discontinuation of EI. Average duration of use was 3.5 years. Mean final TOP on an average of 2.2 medications was 16.9 +/- 5.1 mm Hg 7.9 years following initial glaucoma diagnosis. Four eyes required surgery for uncontrolled IOP. Side-effects included transient redness (3/32 eyes), not necessitating discontinuation of EI. CONCLUSIONS El lowered TOP to within an acceptable range with no significant adverse events. In several patients it was the only pharmacologic agent that was successful.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available